vabase

PIK3CA H1047R

c.3140A>GNM_006218.33-179234297-A-G
PI3K-AKT gain of function transition Cancer hotspot Absent from gnomAD ClinVar: Pathogenic LMGLAKLACCLA

Reports 4 in LM · GLA · KLA · CCLA

ISSVA entityAllele fractionSources
LM 2.33-10.99% (Brouillard 2021: 2.33-10.99%; Li 2023: 2.97-6.7%; Zenner 2022: n.r.)
GLA 23.0% (LM tissue, FFPE; GLA002)
KLA 0.41%
CCLA 0.89%

Bars show the reported allele-fraction range on a 0 to 50 percent axis.

Position in PIK3CA 16 catalogued variants in this gene

PI3K-ABD (16–105)PI3K-ABDPI3K-RBD (187–289)PI3K-RBDC2 PI3K-type (330–487)C2 PI3K-typePIK helical (517–694)PIK helicalPI3K/PI4K catalytic (765–1051)PI3K/PI4K ca…11068 aaR88QE109delE110delN345KC420RP447_L455delE542KE545AE545GE545KQ546KQ546RM1043IH1047LH1047R*1069Pheext*4

Pathway and targeted therapy

Variant in the PI3K-AKT pathway. Repurposed drugs already used in the clinic for this pathway: alpelisib (PI3Kα inhibitor), sirolimus (mTOR inhibitor).

Open and recent trials (4 in vascular / lymphatic anomalies for alpelisib)

Primary sources 4

  1. Genomic profiling informs diagnoses and treatment in vascular anomalies.
    Li D, Sheppard SE, March ME, Battig MR, Surrey LF, Srinivasan AS, Matsuoka LS, Tian L, Wang F, Seiler C, Dayneka J, Borst AJ, Matos MC, Paulissen SM, Krishnamurthy G, Nriagu B, Sikder T, Casey M, Williams L, Rangu S, O'Connor N, Thomas A, Pinto E, Hou C, Nguyen K, Pellegrino da Silva R, Chehimi SN, Kao C, Biroc L, Britt AD, Queenan M, Reid JR, Napoli JA, Low DM, Vatsky S, Treat J, Smith CL, Cahill AM, Snyder KM, Adams DM, Dori Y, Hakonarson H. · Nat Med · 2023
  2. Somatic activating BRAF variants cause isolated lymphatic malformations.
    Zenner K, Jensen DM, Dmyterko V, Shivaram GM, Myers CT, Paschal CR, Rudzinski ER, Pham MM, Cheng VC, Manning SC, Bly RA, Ganti S, Perkins JA, Bennett JT. · HGG Adv · 2022
  3. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
    Brouillard P, Schlögel MJ, Homayun Sepehr N, Helaers R, Queisser A, Fastré E, Boutry S, Schmitz S, Clapuyt P, Hammer F, Dompmartin A, Weitz-Tuoretmaa A, Laranne J, Pasquesoone L, Vilain C, Boon LM, Vikkula M. · Orphanet J Rare Dis · 2021
  4. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly.
    Rodriguez-Laguna L, Agra N, Ibañez K, Ibañez K, Oliva-Molina G, Gordo G, Khurana N, Hominick D, Beato M, Colmenero I, Herranz G, Torres Canizalez JM, Rodríguez Pena R, Vallespín E, Martín-Arenas R, Del Pozo Á, Villaverde C, Bustamante A, Ayuso C, Lapunzina P, Lopez-Gutierrez JC, Dellinger MT, Martinez-Glez V. · J Exp Med · 2019

Mentioned in 3,225 publications indexed by Europe PMC.

Annotations refreshed 2026-10-09 from Europe PMC, ClinVar, ClinicalTrials.gov, gnomAD, and Genome Nexus. Coordinates handled per assembly (gnomAD GRCh38, Genome Nexus GRCh37).